Ohio is currently home to 3183 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
NCT03797391
Recruiting
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2023
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
Register for Updates
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981
Recruiting
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2023
Locations: Gabrail Cancer & Research Center, Canton, Ohio
Conditions: Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer
Register for Updates
International CIPN Assessment and Validation Study
NCT04633655
Recruiting
This is an observational study of chemotherapy-induced peripheral neurotoxicity (CIPN) patients to be investigated prospectively in order to assess responsiveness of a set of outcome measures in an international multi-center study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2023
Locations: Cancer Center/Wexner Medical Center - Ohio State Medical Oncology Division, Columbus, Ohio
Conditions: Chemotherapy-induced Peripheral Neuropathy, Quality of Life
Register for Updates
Biology of Juvenile Myoclonic Epilepsy
NCT03400371
Recruiting
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve pa... Read More
Gender:
ALL
Ages:
Between 10 years and 40 years
Trial Updated:
05/24/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Juvenile Myoclonic Epilepsy
Register for Updates
Diagnostic POCUS of Patellar Tendinopathy in Female Athletes
NCT05880277
Recruiting
Purpose: The purpose of this study is to determine the clinical effectiveness of point-of-care diagnostic ultrasound in the assessment of patellar tendon pathologies
Gender:
FEMALE
Ages:
Between 18 years and 25 years
Trial Updated:
05/18/2023
Locations: Youngstown State University, Youngstown, Ohio
Conditions: Patellofemoral Disorder
Register for Updates
Increased Home-based Physical Therapy Adherence Using BAND Connect's VirtuaCare™ Platform
NCT05876208
Recruiting
This study aims to enhance at-home therapy by introducing a new device called the BAND Connect's VirtuaCare™ platform. The study aims to determine whether patients can improve their adherence to at-home exercises using this device. Currently, research indicates that only 35% of patients undergoing physical therapy treatment fully comply with their prescribed plans of care, often neglecting their at-home exercises. To address this issue, a set of smart exercise tools called VirtuaCare™ has been d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Shoulder Injuries
Register for Updates
ROSE-Longitudinal Assessment With Neuroimaging
NCT05089331
Recruiting
The investigators will perform follow-up on 250 of 500 cases recruited into the ROSE study of cases with deep and lobar intracerebral hemorrhage to perform advanced neuroimaging at 12-24 months post stroke, and evaluations of motor and cognitive function at baseline, 6 months after baseline, and 12 months after baseline to determine predictors of recovery, progressive cognitive or functional impairment. The investigators propose to leverage the recruitment, DNA, RNA-seq and baseline advanced neu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Intracerebral Hemorrhage
Register for Updates
Electroencephalogram (EEG) Enhanced Transcranial Magnetic Stimulation (eTMS) for Chronic Trauma and Stressor-Related Disorders (TSRD)
NCT05835414
Recruiting
The goal of this clinical trial is to learn about the safety, feasibility, and preliminary efficacy of EEG-enhanced transcranial magnetic stimulation (eTMS) as an adjunct to standard-of-care therapies for chronic trauma and stressor related disorders (TSRD) among US military veterans. The main questions the study aims to answer are: * Is it safe to provide 30 sessions of eTMS for veterans with chronic TSRD? * Is it feasible to provide 30 sessions of eTMS as an adjunct to standard-of-care thera... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/03/2023
Locations: BEP Medical Group LLC, Columbus, Ohio
Conditions: Trauma and Stressor Related Disorders
Register for Updates
Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing
NCT05560477
Recruiting
The purpose of this clinical trial is to assess the safety and efficacy of AM3101 to facilitate meniscal repair and reduce the incidence of non-healing complications and morbidities associated with a failed meniscal repair. This is a prospective, randomized, controlled, double-blinded, multi-center study.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
05/01/2023
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Meniscus Tear
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Langerhans Cell Histiocytosis
Register for Updates